Birth certificate

FDA Approves Medicines360's LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Eight Years

Retrieved on: 
Monday, November 14, 2022
SAN, Polyethylene, Internal bleeding, Endometritis, Body mass index, ACCESS, IUS, Pain, Infertility, Levonorgestrel, IUD, Population, PID, Woman, Obstetrics, Faecal calprotectin, Infection, Uterus, American Journal of Obstetrics and Gynecology, Abdominal pain, Risk, Safety, Sores, FDA, Pregnancy, Gynaecology, Ectopic pregnancy, Medicine, Fibroid, Department, HIV, Time, Barium sulfate, Birth certificate, University of Pennsylvania Health System, Vaginal bleeding, Multimedia, American Journal, Pelvic inflammatory disease, Hysterectomy, Death, Patient, Chills, Pelvic pain, Policy, Condom, CEO, BMI, Sex, STD, Allergy, Professor, AbbVie, Review, Perforation, Fever, Food, Shanda, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Birth control, Dietary supplement, Pharmaceutical industry

SAN FRANCISCO, Nov. 14, 2022 /PRNewswire/ -- Medicines360, a global nonprofit organization with a mission to expand women's access to quality medicines, announced today that the U.S. Food and Drug Administration (FDA) has approved Medicines360's Supplemental New Drug Application (sNDA) to extend the duration of use of Liletta® (levonorgestrel-releasing intrauterine system) 52 mg to prevent pregnancy for up to eight years. This approval is based on data from ACCESS IUS (A Comprehensive Contraceptive Efficacy & Safety Study of an IUS) that Medicines360 first published in the American Journal of Obstetrics and Gynecology in May 2022. With this FDA approval, LILETTA has one of the longest approved durations of use for a hormonal intrauterine device (IUD or IUS) in the U.S.

Key Points: 
  • LILETTA was approximately 99% effective in preventing pregnancy for up to eight years in a diverse population of women.
  • LILETTA is a hormone-releasing system placed in the uterus to prevent pregnancy for up to eight years.
  • LILETTA (levonorgestrel-releasing intrauterine system) 52mg is a hormone-releasing system placed in your uterus to prevent pregnancy for as long as you want for up to 8 years.
  • If you get pregnant while using LILETTA, you may have an ectopic pregnancy, which means the pregnancy is not in the uterus.

WHOOP Identifies Novel Pregnancy Digital Biomarker to Screen for Premature Birth

Retrieved on: 
Wednesday, November 9, 2022
Hardware, Health Technology, Retail, Technology, Women, Online Retail, Parenting, Baby, Maternity, Wearables, Mobile Technology, Family, Science, Software, Consumer, Health, Research, YouTube, Review, Health, Research, Reproductive health, Risk, Organization, Parent, Behavior, Diagnosis, Preterm birth, Disease, Mortality, Chief executive officer, Pregnancy, Goal, Data science, HRV, Military personnel, Birth certificate, Infant, Biomarker, Sleep, Woman, Death, CEO, COVID-19, Birth control, Pharmaceutical industry, Instagram, Facebook

At a time when womens health is under attack and it is more difficult than ever for women to access high-quality healthcare , WHOOP has uncovered a first-of-its-kind pregnancy digital biomarker for noninvasive prescreening for premature birth.

Key Points: 
  • At a time when womens health is under attack and it is more difficult than ever for women to access high-quality healthcare , WHOOP has uncovered a first-of-its-kind pregnancy digital biomarker for noninvasive prescreening for premature birth.
  • Understanding this change in HRV, which WHOOP researchers have labeled the WHOOP Inflection Point, has the potential to save lives, reduce medical costs, and provide more insight to expecting parents.
  • Healthcare inequities abound in the United States that disproportionately impact preterm birth rates for black infants (14.2%), American Indian/Alaska Natives (11.6%), and Hispanics (9.8%).
  • The study that WHOOP has conducted is incredibly significant in light of the national public health concerns around premature births.

First Ever “Future of Pregnancy Health” Report Reveals 9 out of 10 New or Expecting Moms Want More Information About Their Individual Risk of Pregnancy Complications to Optimize Prevention

Retrieved on: 
Tuesday, November 8, 2022
Research, Medical Devices, Women, Parenting, Other Health, Biotechnology, General Health, Consumer, Health, Science, Aspirin, Liver, Parent, Ectopic pregnancy, American Heart Association, Khosla Ventures, Mortality, Population, Income, The Harris Poll, Death, Machine learning, Pre-eclampsia, Pregnancy, RNA, GV, Awareness, Placenta, NCHS, United, Entrepreneurship, Medical Affairs Bureau, Blood pressure, Education, Preterm birth, General Catalyst, Disease, Gestational diabetes, Birth certificate, Eclampsia, Marital status, Woman, Biology, Foresite Capital, CDC, Research, Seizure, Risk, Degenerative disease, Complication, White, Incidence, CEO, Birth control, Ephraim Mirvis

Mirvie , a pioneer in predicting unexpected pregnancy complications, today announced the findings of the first ever Future of Pregnancy Health Report .

Key Points: 
  • Mirvie , a pioneer in predicting unexpected pregnancy complications, today announced the findings of the first ever Future of Pregnancy Health Report .
  • The results spotlight an urgent need to identify who is most at risk of complications and tailor education and preventive care toward them.
  • The study also found new or expecting moms overwhelmingly believe knowing their risk of pregnancy complications can enable proactive, personalized and preventive pregnancy care.
  • This new approach to pregnancy health is desperately needed to chart a new course for moms in the United States.

Nuwellis Announces Peer Reviewed Data Demonstrating 71% Survival with Kidney Replacement Therapy Using a Modified Aquadex in Low-Birth-Weight Preterm Neonates

Retrieved on: 
Thursday, November 3, 2022
Company, Palliative care, Private Securities Litigation Reform Act, Science, Overload, Growth, Food, Diuretic, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Ultrafiltration, GLOBE, Hypervolemia, Population, Adult, PMID, Quality of life, National, Kidney failure, COVID-19, Nasdaq, CEO, Birth certificate, CRRT, KBT, Chronic kidney disease, Forward-looking statement, Hospital, NIH, SEC, Sutherland, Patient, Renal replacement therapy, Dialysis, Pharmaceutical industry, Medicine, Pediatrics

Managing neonates with kidney failure can be challenging, as dialysis and other therapies used to treat kidney failure are typically designed for adults or larger pediatric patients.

Key Points: 
  • Managing neonates with kidney failure can be challenging, as dialysis and other therapies used to treat kidney failure are typically designed for adults or larger pediatric patients.
  • These challenges are especially pronounced in preterm neonates.
  • The Company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow system for ultrafiltration therapy.
  • The Aquadex SmartFlow system delivers clinically superior therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload).

Great Wolf Resorts Names John Murphy as Chief Executive Officer

Retrieved on: 
Thursday, November 3, 2022
Entertainment, General Entertainment, Family, Other Travel, Consumer, Lodging, Vacation, Destinations, Tourist Attractions, Travel, Leadership, Growth, Centerbridge Partners, Multimedia, Culture, Foot, Adult, Real estate, YouTube, CEO, Family, Blackstone, IP, Birth certificate, Aimbridge Hospitality, Private investigator, Tourism, Interior design, Amusement park, Hotel, Lagrange (disambiguation), Great Wolf Resorts

Great Wolf Resorts, Inc. announced today that John Murphy, (Murph), will serve as the companys next Chief Executive Officer, taking over for Murray Hennessy who is retiring, but will continue to serve as an advisor to the company.

Key Points: 
  • Great Wolf Resorts, Inc. announced today that John Murphy, (Murph), will serve as the companys next Chief Executive Officer, taking over for Murray Hennessy who is retiring, but will continue to serve as an advisor to the company.
  • While expanding its paw print into new markets with new resorts is an area of focus, Great Wolf Resorts is also investing significantly in its existing resorts.
  • Content featuring the Great Wolf Pack characters is also available on the Great Wolf Entertainment YouTube channel ( The Great Wolf Pack - YouTube ) with additional episodic content available for distribution.
  • Great Wolf Lodge has three resorts currently under construction Great Wolf Lodge Maryland in Perryville, Maryland (opening summer 2023), Great Wolf Lodge South Florida in Naples (mid-2024) and Great Wolf Lodge Gulf Coast Texas in Webster (mid-to-late 2024).

Fetal and Neonatal Care Equipment Market Report 2022: Increasing Incidence of HAIs Among Newborns Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 2, 2022
Consumer, Baby, Maternity, Awareness, Pregnancy, Growth, Nursing credentials and certifications, Revenue, Fetus, Nicu Ceaușescu, Birth certificate, USD, Medical imaging, Medicine

The global Fetal and Neonatal Care Equipment market size is expected to reach USD 14.23 billion by 2030, according to a new study.

Key Points: 
  • The global Fetal and Neonatal Care Equipment market size is expected to reach USD 14.23 billion by 2030, according to a new study.
  • The report "Fetal and Neonatal Care Equipment Market Share, Size, Trends, Industry Analysis Report, By Product (Fetal care Equipment, Neonatal Care Equipment); By End-Use; By Region; Segment Forecast, 2022 - 2030" gives a detailed insight into current market dynamics and provides an analysis of future market growth.
  • The growing demand for fetal and neonatal care equipment due to high preterm rates is expected to drive industry growth.
  • The publisher has segmented the fetal and neonatal care equipment market report based on product, end-use, and region:
    Fetal and Neonatal Care Equipment, Product Outlook (Revenue - USD Billion, 2018 - 2030)

Global Fetal And Neonatal Monitoring Devices Market (2022 to 2031) - Featuring GE Healthcare, Fisher & Paykel Healthcare, Philips Healthcare and Atom Medical Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 1, 2022
Medical Devices, Health, Pregnancy, Growth, FDA Center for Devices and Radiological Health, Incubator, Child, European Economic Area, Ernst, General Data Protection Regulation, Center, Uterus, NMPA, Hospital, MRI, GE Healthcare, Wireless, Infant, Masimo, GDPR, Urban economics, Privacy, Asia-Pacific, Dräger (company), Cerebral palsy, Analogic Corporation, Birth certificate, Philips, FDA, Union, Skin, Regulation of pesticides in the European Union, Prevalence, BD (company), CDRH, Google Images, Device, Light, Doppler fetal monitor, Medical imaging, Medical device, EU, EEA

Major players in the fetal and neonatal monitoring devices and equipment market are GE Healthcare, Fisher & Paykel Healthcare Limited, Philips Healthcare, Atom Medical Corporation, Natus Medical Incorporated, Analogic Corporation, Phoenix Medical Systems (P) Ltd, Becton Dickinson, Masimo Corporation, and Dragerwerk AG & Co. KGAA

Key Points: 
  • Major players in the fetal and neonatal monitoring devices and equipment market are GE Healthcare, Fisher & Paykel Healthcare Limited, Philips Healthcare, Atom Medical Corporation, Natus Medical Incorporated, Analogic Corporation, Phoenix Medical Systems (P) Ltd, Becton Dickinson, Masimo Corporation, and Dragerwerk AG & Co. KGAA
    The fetal and neonatal monitoring devices and equipment market consist of sales of fetal and neonatal monitoring devices and equipment and related services.
  • The main equipment of fetal and neonatal monitoring devices and equipment are fetal and neonatal.
  • Fetal care equipment types are ultrasound devices, fetal dopplers, fetal MRI systems, fetal monitors, and fetal pulse oximeters.
  • Neonatal care equipment types are infant warmers, incubators, convertible warmers and incubators, phototherapy equipment, respiratory devices, neonatal monitoring devices, and diagnostic imaging devices.

ObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium Proceedings

Retrieved on: 
Wednesday, October 26, 2022
IND, Sister republic, SEC, Company, Drug development, Security (finance), Achievement, NASDAQ, Private Securities Litigation Reform Act, Investor, U.S. Securities and Exchange Commission, CEO, JGB, Risk, Coronavirus, Pregnancy, Contract, SIX Swiss Exchange, Hearing, Program, Birth certificate, Report, Compliance, Fertilisation, Woman, Fine chemical, Online gambling, Pharmaceutical industry, Nasdaq, Kissei

These assignments represent savings of approximately $16.0 million in contractual commitments, including $3.7 million of accounts payable.

Key Points: 
  • These assignments represent savings of approximately $16.0 million in contractual commitments, including $3.7 million of accounts payable.
  • On October 20, 2022, ObsEva attended its first hearing with the competent court in Geneva, Switzerland.
  • The Company continues to progress various corporate initiatives intended to resolve its over-indebtedness and support future pipeline development.
  • ObsEva retains worldwide, exclusive, commercial rights, except for the Peoples Republic of China which has been sub-licensed to YuYuan BioScience.

ObsEva Announces IND Approval for Yuyuan Bioscience’s Phase 1 Clinical Trial of Nolasiban in China

Retrieved on: 
Thursday, October 13, 2022
U.S. Securities and Exchange Commission, Female, Sale, Risk, SEC, Achievement, IND, Woman, Sister republic, Investor, NASDAQ, Center for Drug Evaluation and Research, Drug development, Security (finance), SIX Swiss Exchange, Coronavirus, Birth certificate, Fertilisation, Private Securities Litigation Reform Act, Report, Pharmacokinetics, CEO, Adult, IVF, Safety, Infertility, Center, Pregnancy, Compliance, Pharmaceutical industry, Nasdaq

Nolasiban is a novel, oral oxytocin receptor antagonist being developed to improve clinical pregnancy and live birth rates in women undergoing in vitro fertilization.

Key Points: 
  • Nolasiban is a novel, oral oxytocin receptor antagonist being developed to improve clinical pregnancy and live birth rates in women undergoing in vitro fertilization.
  • Yuyuan plans to initiate a single-center, randomized, double-blind, placebo-controlled Phase 1 clinical trial in China to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic characteristics of nolasiban in healthy adult female subjects in China.
  • The Phase 1 clinical trial planned by Yuyuan, including testing varying dose levels and duration of dosing, will provide critical observations that will inform nolasibans future development in the United States and abroad.
  • ObsEva has sublicensed the exclusive rights to develop and commercialize nolasiban in the Peoples Republic of China to Yuyuan.

ProgenyHealth Releases New Report on Innovations in Maternity Care Management

Retrieved on: 
Tuesday, October 4, 2022
Linda, Disease, Anxiety, Physician, Case management, Mother, Research, Parenting, Midwifery, CEO, Health, Diet, Family, MPH, Birth certificate, LLC, Health equity, Medicaid, Nursing, Social, Pregnancy, Organization, Infant, Woman, NICU, Birth control, Animal, MD

PLYMOUTH MEETING, Pa., Oct. 4, 2022 /PRNewswire/ -- ProgenyHealth, LLC, a leading, tech-enabled women's health company dedicated to Maternity and NICU Care Management, has released a new report highlighting the importance of national "Innovations in Maternity Care Management." As 1 in every 10 babies in the United States continue to be born prematurely, there is an ongoing crisis in maternal health and maternal health equity that healthcare stakeholders must address.

Key Points: 
  • Complications and costs are rising despite the United States spending more per capita than any other country on healthcare.
  • For more information on the "Innovations in Maternity Care Management" findings, including insights on quality improvements and cost savings such as NICU utilization management and payment validation , visit ProgenyHealth.com or click here to view the report.
  • ProgenyHealth is a leading national, tech-enabled women's health company dedicated to Maternity and NICU Care Management.
  • Our industry-leading intelligent platform, Baby Trax, integrates utilization management and case management, while driving payment validation & assurance activities based on clinical data.